EUVIMEDEUVIMED entdecken
Systematische Übersicht

PrEP for women in Europe: a systematic literature review

Naomi Fitzgerald, Holly Coltart, Lourdes Dominguez iD, Kate Flanagan, Yvonne Gilleece

HIV Medicine · 2023-07 · 24 (7) · 765-776

DOI: 10.1111/hiv.13458 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift HIV Medicine, online erschienen am 23.04.2023. Verfasst von Naomi Fitzgerald und 4 weiteren Autor:innen. Beteiligte Einrichtung: King's College Hospital, London, UK. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Sexual and Gender Minorities, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: European AIDS Clinical Society (EACS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prevention of HIV transmission is fundamental to ending the HIV epidemic. Pre‐exposure prophylaxis (PrEP) with oral tenofovir‐emtricitabine (TDF‐FTC) is an established HIV‐prevention method; however, most PrEP services in Europe have been targeted at men who have sex with men (MSM). A survey in 2021 by Women Against Viruses in Europe (WAVE) showed considerable variation in PrEP access and guidance for women throughout Europe. WAVE therefore commissioned this systematic review to provide insight into PrEP provision and barriers to uptake for women in Europe.

Methods

PubMed, Embase, and Scopus were searched for studies (January 2013–May 2021) that reported on actual (e.g., efficacy and safety) or hypothetical (e.g., awareness, barriers, PrEP impact models) use of oral PrEP involving women (including cis, transgender, pregnant, migrant, and breastfeeding women). Search terms included HIV, pre‐exposure prophylaxis (specifically TDF‐FTC), and women. Studies performed outside of the World Health Organization European region were excluded.

Results

The search identified 4716 unique citations, and 45 peer‐reviewed articles (44 studies) were included. The majority of these studies (34/44 [77%]) included recipients or potential recipients of PrEP, representing 4699 women (243 transgender women). However, few studies were women focused (4/34 [12%]) or took place outside of Western Europe (3/34 [9%]). Across the three clinical studies that reported women‐specific outcomes (60 transgender women, 13 pregnant, and 19 cis women), no breakthrough infections were recorded during the use of PrEP. Lack of awareness of PrEP, low self‐estimation of HIV acquisition risk, concerns about stigma, lack of protection against other sexually transmitted infections, and PrEP interaction with hormones (for transgender women) were identified as barriers to use. The remaining studies examined healthcare professionals' perceptions of PrEP (9/44 [20%]), asked for public opinion (2/44 [5%]), or modelled the potential of PrEP for HIV prevention (1/44 [2%]).

Conclusions

This review revealed a notable lack of literature on PrEP for cis and transgender women in Europe. This is synonymous with a lack of PrEP provision for women in this region. Barriers to PrEP uptake are complex and rooted in institutional and societal stigma, which must be addressed at policy level. HIV prevention with PrEP is not ‘one size fits all’ and requires a nuanced gender‐responsive approach. Further research into the use of PrEP in cis, pregnant, breastfeeding, and transgender women is essential if we are to stop HIV transmission by 2030.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsSexual and Gender MinoritiesPre-Exposure ProphylaxisMalePregnancyHumansFemaleHomosexuality, MaleTenofovirEmtricitabine

Stichwörter der Autor:innen

EuropeHIVPrEPPre-exposure prophylaxiscis womentransgender women

Substanzen

Anti-HIV AgentsTenofovirEmtricitabine

Autor:innen und Institutionen

  • King's College Hospital, London, UK.
  • Brighton & Sussex Medical School, Brighton, UK.
  • The Lawson Unit, Royal Sussex County Hospital, Brighton, UK.

ORCID-Profile: Lourdes Dominguez

Förderung

  • European AIDS Clinical Society (EACS)

Zitieren

APA

Fitzgerald, N., Coltart, H., Dominguez, L., Flanagan, K., & Gilleece, Y. (2023). PrEP for women in Europe: a systematic literature review. HIV Medicine, 24(7), 765-776. https://doi.org/10.1111/hiv.13458

Vancouver

Fitzgerald N, Coltart H, Dominguez L, Flanagan K, Gilleece Y. PrEP for women in Europe: a systematic literature review. HIV Medicine. 2023;24(7):765-776. doi:10.1111/hiv.13458

BibTeX
@article{Fitzgerald2023,
  author = {Fitzgerald, Naomi and Coltart, Holly and Dominguez, Lourdes and Flanagan, Kate and Gilleece, Yvonne},
  title = {PrEP for women in Europe: a systematic literature review},
  journal = {HIV Medicine},
  year = {2023},
  volume = {24},
  number = {7},
  pages = {765--776},
  doi = {10.1111/hiv.13458}
}
Kostenlos starten →